Replies to post #4583 on EKO International Inc (EKNL)

[TheBullEconomist]

A $1 pps then $2 uplisting, will bring a myriad of institutional investors, and moreover, buyout/mergers offers.
I haven't read the clinical outcomes studies; if EKO has THE viable diabetic neuropathy product, a buyout is imminent with a much higher pps than what is being expected.